LV232

LV232 is a small molecule drug developed by Suzhou Vigonvita Life Sciences for the treatment of major depressive disorder (MDD). It is currently in Phase 2 clinical trials, with its primary therapeutic area being nervous system diseases, specifically depressive disorders. A Phase 1 exploratory study using positron emission tomography (PET) investigated LV232’s occupancy of the serotonin transporter (5-HTT) in the human brain after oral administration, suggesting that its antidepressant effect may be mediated through modulation or inhibition of the serotonin transporter. The drug is administered orally and has undergone multiple ascending dose and food-effect studies to evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.